• Featured Product
  • KD/KO Validated

PRAME Monoclonal antibody

PRAME Monoclonal Antibody for WB, IF, ELISA

Host / Isotype

Mouse / IgG2b


Human, mouse, rat







Cat no : 68097-1-Ig


MAPE, OIP 4, OIP4, Opa interacting protein 4, PRAME

Tested Applications

Positive WB detected inA549 cells, HeLa cells, A375 cells, mouse testis tissue, K-562 cells, U2OS cells
Positive IF detected inHaCaT cells

Recommended dilution

Western Blot (WB)WB : 1:5000-1:50000
Immunofluorescence (IF)IF : 1:400-1:1600
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

68097-1-Ig targets PRAME in WB, IF, ELISA applications and shows reactivity with Human, mouse, rat samples.

Tested Reactivity Human, mouse, rat
Host / Isotype Mouse / IgG2b
Class Monoclonal
Type Antibody
Immunogen PRAME fusion protein Ag1906
Full Name preferentially expressed antigen in melanoma
Calculated Molecular Weight 509 aa, 58 kDa
Observed Molecular Weight50 kDa
GenBank Accession NumberBC014074
Gene Symbol PRAME
Gene ID (NCBI) 23532
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.


Product Specific Protocols
WB protocol for PRAME antibody 68097-1-IgDownload protocol
IF protocol for PRAME antibody 68097-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols